PhaseRx is developing RNA nanomedicines for the treatment of orphan diseases. The Company’s innovative approach to drug discovery and development is based on its proprietary SMARTT Polymer Technology®, which offers effective mRNA delivery, a favorable side effect profile and robust and scalable manufacture.